The U.S. Food and Drug Administration (FDA) has cleared Siemens Healthineers' Acuson Origin AI-powered cardiovascular ultrasound system.
Acuson Origin. Image courtesy of Siemens Healthineers.
Acuson Origin can be used for diagnostic, structural heart, vascular, electrophysiological, and pediatric procedures in cardiovascular care, according to Siemens. The system can produce more than 5,600 AI-powered measurements on transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE), Siemens said.
AI Assist, a new feature for TTE, recognizes cardiac structures immediately and automatically positions color and spectral Doppler regions of interest when the transducer makes contact with the chest wall, Siemens added. The system also provides automated contouring and quantification of all four cardiac chambers without the need for an electrocardiogram (ECG) via the 2D and 4D HeartAI features.
Additionally, Siemens noted that the AcuNav Lumos 4D intracardiac echocardiography (ICE) catheter is designed exclusively for Acuson Origin. AcuNav Lumos 4D ICE enables interventional cardiologists and electrophysiologists to treat patients who otherwise would be unable to undergo structural heart interventions, including patients with TEE or general anesthesia contraindications, and patients with tricuspid regurgitation, Siemens said.
